Form 4: Ligand Pharmaceuticals President & COO Matthew Korenberg Reports Stock Option Exercises and Disposals
SEC Form 4 Filing
Matthew Korenberg, President & COO of Ligand Pharmaceuticals, reports exercising stock options and disposing of shares to cover tax obligations on September 16, 2024.
Summary
- On September 16, 2024, Matthew E. Korenberg, President & COO of Ligand Pharmaceuticals, executed multiple transactions involving common stock and employee stock options.
- Korenberg exercised employee stock options to acquire a total of 5,764 shares of common stock at prices ranging from $49.99 to $60.94.
- Simultaneously, Korenberg disposed of 3,114 shares of common stock at a price of $105 to satisfy tax obligations related to the option exercises.
- Following these transactions, Korenberg directly owns 52,070 shares of Ligand Pharmaceuticals common stock.
- He also holds derivative securities, including employee stock options, for a significant number of shares.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reflects routine transactions by an executive. The exercise of options is a positive signal, but the sale to cover taxes is a neutral event.
Positives
- The exercise of stock options indicates Korenberg's confidence in the company's future prospects.
Negatives
- The disposal of shares to cover tax obligations could be perceived as a slight negative, although it's a common practice.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in company stock.
Comparison to Industry Standards
- Insider trading activity is common across publicly listed companies, and the reported transactions appear to be standard exercises of stock options and sales to cover tax liabilities.
- Comparable companies in the pharmaceutical sector also have executives who regularly file Form 4s to report similar transactions.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are routine and do not indicate any fundamental change in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 08/06/2015 | Grant of 25,000 shares on August 06, 2015, which vested in full on August 06, 2019, at an exercise price of $104.59 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| 02/11/2016 | Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| 02/24/2017 | Grant of 15,225 shares on February 24, 2017, which vested in full on February 24, 2021, at an exercise price of $100.38 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| 02/13/2020 | Grant of 30,750 shares on February 13, 2020, at an exercise price of $95.68 per share , but was adjusted pursuant to the OmniAb Inc. separation from the issuer, then vested in full on February 13, 2024. |
| 09/16/2024 | Date of the reported transactions: exercise of stock options and disposal of shares. |
| 09/18/2024 | Date of the Form 4 filing. |
| 02/11/2026 | Expiration date for one of the employee stock options. |
| 02/24/2027 | Expiration date for one of the employee stock options. |
| 02/13/2030 | Expiration date for one of the employee stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.